Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Preclinical, early phase clinical trials and epidemiological evidence support the potential role of insulin-sensitizers in cancer prevention and treatment. Insulin-sensitizers improve the metabolic and hormonal profile in PCOS patients and may also act as anticancer agents, especially in cancers associated with hyperinsulinemia and oestrogen dependent cancers. Several lines of evidence support the protection against cancer exerted by dietary inositol, in particular inositol hexaphosphate. Metformin, thiazolidinediones, and myoinositol postreceptor signaling may exhibit direct inhibitory effects on cancer cell growth. AMPK, the main molecular target of metformin, is emerging as a target for cancer prevention and treatment. PCOS may be correlated to an increased risk for developing ovarian and endometrial cancer (up to threefold). Several studies have demonstrated an increase in mortality rate from ovarian cancer among overweight/obese PCOS women compared with normal weight women. Long-term use of metformin has been associated with lower rates of ovarian cancer. Considering the evidence supporting a higher risk of gynaecological cancer in PCOS women, we discuss the potential use of insulin-sensitizers as a potential tool for chemoprevention, hypothesizing a possible rationale through which insulin-sensitizers may inhibit tumourigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 2×
“through an increase of intracellular ADP : ATP ratio, which leads to the inhibition of respiratory chain and subsequent AMPK phosphorylation [62].”
BackgroundFauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“All these lines of evidence suggest, as stated by the 3rd PCOS Consensus Group [168], that there are moderate-quality data supporting the high risk of PCOS women for developing endometrial cancer, with consequent need for increased awareness for surveillance strategies.”
ResultThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“Furthermore, metformin plays an essential role in the inhibition of hepatic gluconeogenesis [169] with the consequent decrease in insulin levels.”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638 · cited 1×
“Myo-Ins is an important component of the structural lipids and its various phosphates, including the phosphatidylinositol phosphate (PIP) lipids [102–104], are essential inmaintaining the cellular membrane bilayer.”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“AMPK activation by metformin induces fatty acid oxidation, reduces lipid synthesis, and inhibits gluconeogenesis [63, 64].”
BackgroundManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Cited by
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Self-citationAl Wattar, B. H., Bueno, A., Martin, M. G., Ibáñez, N. C., Harasani, K., Garad, R., Franks, S., Balen, A., Bhide, P., Piltonen, T., et al. (2021) · Human Reproduction · doi:10.1093/humrep/deaa331 · Cited by 14
“Epidemiological studies helped to crystallize the risk of endometrial cancer in this group and prompted the introduction of preventative treatments into routine care (Lauretta et al., 2016; MacKintosh and Crosbie, 2018).”
Background
Metadata
- Authors
- Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., & Appetecchia, M.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-17
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W2521297707
- Cited by
- 36
- References
- 34
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. https://app.cochat.ai/papers/10.1155/2016/8671762
- The paper
- Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., & Appetecchia, M. (2016). Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. International Journal of Endocrinology. https://doi.org/10.1155/2016/8671762
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.